8-K: VolitionRx Amends, Exercises Over-Allotment Option

VolitionRx Limited amended its underwriting agreement to allow for partial exercise of its over-allotment option, leading to the sale of additional shares and warrants.

Summary

• VolitionRx Limited amended its Underwriting Agreement with Newbridge Securities Corporation on November 7, 2025.
• The amendment modified the terms of the 30-day Over-Allotment Option, allowing the underwriter to exercise for solely common stock, solely warrants, or any combination thereof, rather than only combined.
• Concurrently with the amendment, the underwriter exercised its Over-Allotment Option to purchase 1,194,000 additional common shares and 1,732,500 additional common stock purchase warrants.
• These securities were sold at the same combined offering price of $0.52 ($0.51 per share, $0.01 per warrant), less a 7.0% underwriting discount.
• The net proceeds to the company from this exercise are approximately $566,398.20 from shares and $16,111.25 from warrants, totaling approximately $582,509.45.

Sentiment

Score: 6

Explanation: The exercise of the over-allotment option is generally positive as it brings in additional capital, indicating demand for the offering. However, the dilution for existing shareholders and the relatively low price point temper the overall positive sentiment.

Positives

• Successfully raised additional capital of approximately $582,509.45 through the exercise of the over-allotment option.
• The amendment provides greater flexibility for the underwriter to exercise the option, potentially optimizing future capital raises.
• The exercise demonstrates continued interest from the underwriter in the company's securities.

Negatives

• The exercise of the over-allotment option results in further dilution for existing shareholders due to the issuance of additional common stock and warrants.
• The shares and warrants were sold at a discounted price of $0.52 per unit (before underwriting fees), which is a relatively low price point.

Risks

• Dilution of existing shareholders' ownership percentage and earnings per share due to the issuance of additional common stock and warrants.
• Potential downward pressure on the stock price if the newly issued shares and warrants are sold in the open market.
• Future exercise of the remaining warrants could lead to further dilution.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the completion of the over-allotment option exercise.

Management Comments

• The Amendment permits the Underwriter, in its sole discretion, to exercise the Over-Allotment Option with respect to solely Option Shares, solely Option Warrants, or any combination thereof, rather than only as a combined exercise for both Option Shares and Option Warrants together.

Industry Context

This capital raise through an over-allotment option exercise is a standard mechanism for publicly traded companies to secure additional funding following an initial public offering or secondary offering. It reflects the company's ongoing need for capital, likely for operational expenses, research and development, or general corporate purposes, common for biotech or diagnostic companies like VolitionRx.

Stakeholder Impact

• Shareholders: Experience dilution of their ownership percentage and potential dilution of earnings per share due to the issuance of additional common stock and warrants.
• Company: Benefits from additional capital infusion, which can be used for general corporate purposes, research and development, or to strengthen its balance sheet.
• Underwriter (Newbridge Securities Corporation): Earns underwriting fees from the transaction.

Next Steps

• The company will receive the net proceeds from the exercised over-allotment option.
• The newly issued shares and warrants will be integrated into the market.

Key Dates

Keywords

VolitionRx, VNRX, Underwriting Agreement, Over-Allotment Option, Common Stock, Warrants, Capital Raise, Public Offering, SEC Filing, Dilution